Search Results
Your search for early matches 10493 pages
Showing 1451 - 1500Addition of Nivolumab to Stereotactic Ablative Radiotherapy in Early-Stage or Isolated Lung Parenchymal Recurrent NSCLC
In a phase II trial (I-SABR) reported in The Lancet, Joe Y. Chang, MD, of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the addition of immunotherapy with nivolumab to stereotactic ablative radiotherapy (SABR) improved ...
Risk Factors for Incident Heart Failure Among Cancer Survivors Aged 18 to 39
In a study reported in a research letter in JACC: CardioOncology, Hibler et al found that survivors of young adult cancers who were exposed to anthracyclines were at an increased risk of subsequent diagnosis of heart failure. Study Details The study involved electronic health record data from the...
Radiation Exposure From Medical Imaging in Pediatric Patients With Down Syndrome
Pediatric patients with Down syndrome may undergo almost 10 times as many medical imaging examinations as other pediatric patients, potentially exposing them to more ionizing radiation, according to a recent study published by Marlow et al in PLOS ONE. Background Ionizing radiation is present in...
ASCO Participates in President’s Cancer Panel Event
ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...
Aaron C. Tan, PhD, MBBS, on Circulating Tumor DNA: Early Biomarker of Therapeutic Response in Phase I Trials
Aaron C. Tan, PhD, MBBS, of the National Cancer Centre Singapore, discusses new findings on early evaluation of circulating tumor DNA via low-pass whole-genome sequencing. The results of his study suggest this method may represent an early pharmacodynamic biomarker of therapeutic response...
High-Grade Serous Ovarian Cancer: Impact of Multimodal Screening on Survival
In an analysis of the UKCTOCS study reported in The Lancet Oncology, Menon et al found that patients with high-grade serous tubo-ovarian cancer detected on multimodal screening may have a survival benefit over those whose disease was diagnosed without screening. The investigator stated, “In...
Enhanced Recovery Program May Be Effective at Reducing Opioid Use After Pancreatic Cancer Surgery
Improving hospital care pathways may help reduce inpatient opioid use by 50% and cut the median opioid prescription volumes at discharge to zero in patients undergoing pancreatic cancer surgery, according to a recent study published by Boyev et al in JAMA Surgery. The new findings could help reduce ...
Phase III Trial Reports Chemoimmunotherapy Is Superior to Chemotherapy Alone in Malignant Pleural Mesothelioma
Patients with malignant pleural mesothelioma who were treated with a chemoimmunotherapy regimen containing the immune checkpoint inhibitor pembrolizumab experienced significantly improved overall survival compared with those treated with chemotherapy alone, with acceptable tolerability, according...
Can AI Assessment of Screening Mammograms Offer Similar Accuracy to Human Readers?
A commercially available artificial intelligence (AI) algorithm may perform comparably to human readers at assessing screening mammograms, according to a recent study published by Chen et al in Radiology. False-positive interpretations on screening mammograms can result in women without cancer...
New Clinical Trial Seeks to Reduce Cardiovascular Damage in Patients Undergoing Anticancer Therapy for Breast Cancer
Researchers have launched a new clinical trial examining the effectiveness of behavioral and psychological interventions at reducing cardiovascular damage caused by anticancer therapies in patients with breast cancer. Background Breast cancer—the most common cancer type in the European...
Optimizing Tobacco Cessation Treatment With Lung Cancer Screenings
The Program for Lung Cancer Screening and Tobacco Cessation trial tested different adaptive interventions based on the evidence-based Tobacco Longitudinal Care (TLC) program, in part to learn how best to incorporate TLC into annual lung cancer screening as a smoking cessation standard. The findings ...
Study Shows Potential of Cabozantinib to Treat Patients With Advanced Neuroendocrine Tumors
An interim analysis of the CABINET trial has shown that the phase III pivotal trial has met its primary endpoint, according to a press release from the Alliance for Clinical Trials in Oncology. Cabozantinib demonstrated statistically significant and clinically meaningful improvements in...
Patterns in Early-Onset Cancer Incidence in the United States From 2010 to 2019
In a study using SEER (Surveillance, Epidemiology, and End Results) registry data reported in JAMA Network Open, Koh et al found that the incidence of cancer among individuals in the United States younger than age 50 years—defined as early-onset cancer—increased significantly between 2010 and 2019. ...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel...
Sacituzumab Govitecan-hziy Continues to Show Benefit in Patients With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
The antibody-drug conjugate sacituzumab govitecan-hziy continued to demonstrate superior benefit for patients with hormone receptor–positive, HER2-negative metastatic breast cancer when compared with standard chemotherapy, according to the final analysis of the phase III TROPiCS-02 study published...
Crystal S. Denlinger, MD, FACP, Named New Chief Executive Officer of NCCN
On August 23, 2023, the National Comprehensive Cancer Network® (NCCN) announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger, who is currently Senior Vice President and Chief Scientific Officer of NCCN, will lead the global guidelines organization...
Personalized Calculator May Be Predictive of Benefits From Adjuvant TACE in Patients With Hepatocellular Carcinoma Undergoing Hepatectomy
Researchers have developed a personalized calculator that may be capable of predicting the reduced risk of early recurrence in patients with hepatocellular carcinoma, according to a recent study published by Chen et al in eGastroenterology. Background Hepatocellular carcinoma is the most common...
Targeted Axillary Dissection After Neoadjuvant Therapy in Node-Positive Breast Cancer
In a German prospective registry study (SenTa) reported in JAMA Surgery, Kuemmel et al found that targeted axillary dissection alone after neoadjuvant systemic therapy was associated with outcomes similar to those obtained with targeted axillary dissection plus axillary lymph node dissection in...
Developing Solutions for Cancer Care Disparities Across Geography
Understanding the complexities of health disparities within cancer care requires an exploration beyond immediate clinical factors. According to Elisa Rodriguez, PhD, MS, of Roswell Park Comprehensive Cancer Center, Buffalo, New York, geography plays a critical role in defining health outcomes in...
How the Cancer Moonshot Aims to Improve the Quality of Life for Adolescent and Young Adult Cancer Survivors
Several recent studies have shown an increasingly disturbing trend: the incidence of early-onset cancers—those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as well. Worldwide, in 2019, there were a reported 1.19 million new cases of...
Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management
A new ASCO guideline rapid update provides updated recommendations for the management of stage III non–small cell lung cancer (NSCLC). These updated recommendations made by the ASCO expert panel cover treatment options for patients with resected disease and specific genetic mutations as well as...
Noninvasive, Multitarget Stool DNA Methylation Assay Under Study in Early Detection of Multiple Gastrointestinal Cancers
A prospective study in China found that a noninvasive, multitarget stool DNA methylation assay was accurate in the early detection and identification of the tissue of origin of gastrointestinal cancers.1 The study, conducted by Li-Yue Sun, MD, of Guangdong Second Provincial General Hospital,...
Understanding How TET2 Gene Deficiency May Fuel Development of AML
Researchers may have identified how the TET2 gene may fuel rapid cancer growth in patients with acute myeloid leukemia (AML), according to a recent study published by Li et al in Cell Stem Cell. Background AML is distinguished by the rapid division and metastasis of immature leukemia stem cells....
Are All Benzodiazepines Created Equal in Terms of Survival in Patients With Pancreatic Cancer?
Patients with pancreatic cancer who were treated with the benzodiazepine lorazepam had shorter progression-free survival periods than patients who were not, according to study results published by Cornwell et al in Clinical Cancer Research. In contrast, patients who were treated with the...
Liquid Biopsy Assay Demonstrated Effectiveness in Early Cancer Detection in Asymptomatic Individuals in Vietnam
A Vietnamese prospective study by Hanh Thi-Hue Nguyen, BS, and Le Son Tran, PhD, both of the Medical Genetics Institute and Gene Solutions, Ho Chi Minh City, Vietnam, and colleagues, investigating the feasibility and performance of a circulating tumor DNA (ctDNA) analyzing test in the early...
ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer
Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...
MD Anderson Names Christopher Flowers, MD, MSc, FASCO, Division Head of Cancer Medicine
The University of Texas MD Anderson Cancer Center recently announced the appointment of Christopher Flowers, MD, MSc, FASCO, a physician-scientist and leader in oncology, as Division Head of Cancer Medicine. This is the largest academic division at MD Anderson, including 13 clinical academic...
Chemotherapy Shortage Impacts Patients, Physicians, Costs, and Clinical Trials
Grim, grimmer, and grinding are among the terms reported in the press to describe the current chemotherapy shortage.1,2 And, “it is not going away,” Mark J. Ratain, MD, FASCO, Chief Hospital Pharmacologist, University of Chicago Medicine, told The ASCO Post. “This is a progressive problem like...
Effects of BMI in Patients With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Palbociclib and Endocrine Therapy
In a preplanned analysis of the phase III PALLAS trial reported in the Journal of Clinical Oncology, Pfeiler et al found that higher body mass index (BMI) reduced the risk of neutropenia and treatment discontinuation in patients with early hormone receptor–positive breast cancer receiving adjuvant...
Diagnosing Early-Stage Bladder Cancer in Patients With Hematuria: Novel mePENK Test
Researchers have found that the new PENK methylation (mePENK) test could potentially pave the way for a breakthrough in early bladder cancer detection in patients with hematuria, according to a novel study published by Oh et al in The Journal of Molecular Diagnostics. The findings could reduce the...
Expert Point of View: Michiel S. Van der Heijden, MD, PhD
Formal discussant of the CheckMate 274 trial, Michiel S. Van der Heijden, MD, PhD, of the Netherlands Cancer Institute, said it is an “important” study. “In looking at these results, one should consider the goal of adjuvant therapy in this setting. Is overtreatment of patients cured by surgery...
Neoadjuvant Pembrolizumab/Chemotherapy and Adjuvant Pembrolizumab in Early-Stage NSCLC
As reported in The New England Journal of Medicine by Heather Wakelee, MD, and colleagues, an interim analysis of the phase III KEYNOTE-671 trial showed that the addition of neoadjuvant pembrolizumab to cisplatin-based chemotherapy followed by adjuvant pembrolizumab improved pathologic response and ...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
Three Studies From ASCO 2023 Focus on Metastatic Castration-Resistant Prostate Cancer
Presented here are summaries of three abstracts from the 2023 ASCO Annual Meeting that are pertinent for patients with metastatic castration-resistant prostate cancer. The first two focus on men with homologous recombinant repair (HRR) gene alterations, including BRCA1/2. In the first study,...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
Expert Point of View: David A. Braun, MD, PhD
David A. Braun, MD, PhD, of Yale Cancer Center, was the formal discussant of the abstract on the 4-year follow-up of the CLEAR trial. “We have made remarkable progress [in advanced renal cell carcinoma] and are now in the combination era of immunotherapy-based therapy and immunotherapy-based...
Genitourinary Oncology 2023 Almanac
It is an exciting time in the development of new treatments for urologic cancers. There have been a number of major changes both in advanced disease and in the perioperative setting over the past year. Urothelial and Bladder Cancers In urothelial cancer, at last, we have randomized data supporting...
Elranatamab Induces Responses in Many Patients With Resistant Multiple Myeloma in Phase II Trial
The promise of bispecific monoclonal antibodies in multiple myeloma continues to heighten as yet another one appears to be active. In a study reported at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition,1 almost two-thirds of patients with triple-refractory disease who...
Expert Point of View: Ciara L. Freeman, MD, PhD and Asher Chanan-Khan, MD
Ciara L. Freeman, MD, PhD, Assistant Member, Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida, was impressed with the CARTITUDE-4 findings. She said “treaters and patients” will be “watching this space” to see how the results change the...
CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
CAR T-Cell Therapy vs Chemoimmunotherapy in Second-Line Treatment of Resistant Large B-Cell Lymphoma
New research has confirmed the superiority of lisocabtagene maraleucel over the standard of care for the second-line treatment of primary refractory or early relapsed large B-cell lymphoma, according to data presented by lead study author Jeremy S. Abramson, MD, Associate Professor of Medicine at...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
Expert Point of View: Caron Jacobson, MD
Caron Jacobson, MD, shared some comments on ZUMA-7 with The ASCO Post. She called ZUMA-7 “an extremely important study to advance the care of high-risk early relapsing or primary refractory large B-cell lymphoma after front-line chemoimmunotherapy.” Dr. Jacobson is Assistant Professor of Medicine...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
Hematologic Oncology 2023 Almanac
The past several months have brought significant advances within the field of hematologic oncology. Here we will review some key updates focusing on pivotal clinical trials and new drug approvals. Advances in Lymphoma Presented at the 2023 ASCO Annual Meeting, SWOG S1826 compared nivolumab plus...
T-Cell Tolerant Fraction May Predict Immune-Related Adverse Events Among Patients Receiving Immunotherapy
Researchers have identified a novel parameter of T cells that may help oncologists anticipate which patients are most likely to develop immunotherapy toxicity. The findings, published by Ostmeyer in the Journal for ImmunoTherapy of Cancer, could lead to improved treatments for a variety of ...
AI-Driven Muscle Mass Assessment May Aid in Detecting Sarcopenia in Patients With Head and Neck Cancer
Researchers have found a way to use artificial intelligence (AI) to diagnose sarcopenia in patients with head and neck cancer. The tool may be used to improve treatment and supportive care for patients, according to a report published by Ye et al in JAMA Network Open. “Sarcopenia is an indicator...
American Society for Radiation Oncology Names Newly Elected Officers to Board of Directors
The members of the American Society for Radiation Oncology (ASTRO) recently elected three new officers to ASTRO’s Board of Directors: Sameer Keole, MD, FASTRO, as President-Elect; Wendy Woodward, MD, PhD, FASTRO, as Science Council Vice Chair; and Vivek S. Kavadi, MD, MBA, FASTRO, as Health Policy...
